10q10k10q10k.net
Simulations Plus, Inc.

Simulations Plus, Inc.SLPEarnings & Financial Report

Nasdaq · software industry

Simulations Plus, Inc. develops absorption, distribution, metabolism, excretion, and toxicity (ADMET) modeling and simulation software for the pharmaceutical and biotechnology, industrial chemicals, cosmetics, food ingredients, and herbicide industries. In September 2014, the company acquired Cognigen Corporation, a provider of clinical trial data analysis and consulting services.

SLP Q1 2026 Key Financial Metrics

Revenue

$18.4M

Gross Profit

$10.9M

Operating Profit

$713.0K

Net Profit

$676.0K

Gross Margin

59.1%

Operating Margin

3.9%

Net Margin

3.7%

YoY Growth

-2.7%

EPS

$0.03

Financial Flow

Simulations Plus, Inc. Q1 2026 Financial Summary

Simulations Plus, Inc. reported revenue of $18.4M for Q1 2026, with a net profit of $676.0K (3.7% margin). Cost of goods sold was $7.5M, operating expenses totaled $10.2M.

Key Financial Metrics

Total Revenue$18.4M
Net Profit$676.0K
Gross Margin59.1%
Operating Margin3.9%
Report PeriodQ1 2026

Simulations Plus, Inc. Annual Revenue by Year

Simulations Plus, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $79.2M).

YearAnnual Revenue
2025$79.2M
2024$70.0M
2023$59.6M
2022$53.9M

Income Statement

Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026
Revenue$18.3M$18.5M$18.7M$18.9M$22.4M$20.4M$17.5M$18.4M
YoY Growth16.2%14.2%19.4%30.5%22.5%9.8%-6.5%-2.7%

Balance Sheet

Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026
Assets$194.0M$192.7M$196.6M$196.9M$201.4M$134.4M$131.9M$137.8M
Liabilities$16.9M$11.8M$14.2M$12.2M$11.9M$10.6M$7.1M$10.7M
Equity$177.0M$180.9M$182.4M$184.7M$189.5M$123.8M$124.8M$127.1M

Cash Flow

Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026
Operating CF$5.8M$5.7M$1.7M$-1.3M$5.7M$8.1M$5.6M$4.2M